Cover Image
市場調查報告書

全球類鴉片物質市場:各類藥物(促效劑(可待因,芬太尼,哌替啶,美沙酮,嗎啡,氫可酮,地芬諾酯,氫嗎啡酮,其他),拮抗劑),各治療用途,各地區 - 趨勢與產業預測

Opioids Market, by Drug Class, Therapeutic Application, and Geography - Trends and Forecast till 2025

出版商 Coherent Market Insights 商品編碼 593048
出版日期 內容資訊 英文 313 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球類鴉片物質市場:各類藥物(促效劑(可待因,芬太尼,哌替啶,美沙酮,嗎啡,氫可酮,地芬諾酯,氫嗎啡酮,其他),拮抗劑),各治療用途,各地區 - 趨勢與產業預測 Opioids Market, by Drug Class, Therapeutic Application, and Geography - Trends and Forecast till 2025
出版日期: 2017年11月09日 內容資訊: 英文 313 Pages
簡介

本報告提供全球類鴉片物質市場相關調查,彙整市場概要和各類藥物,各治療用途,及各地區的趨勢,加入此市場的主要企業的簡介等資料。

第1章 調查目的與假設

第2章 市場概要

第3章 市場趨勢,法律規章,趨勢分析

  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 市場機會
  • 法律規章方案
  • 給付方案
  • 價格分析
  • 新產品上市
  • 政府的政策與取組

第4章 各類藥物市場

  • 簡介
  • 促效劑
  • 可待因
  • 芬太尼
  • 哌替啶
  • 美沙酮
  • 嗎啡
  • 氫可酮
  • 地芬諾酯
  • 氫嗎啡酮
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone

第5章 各治療用途市場

  • 簡介
  • 疼痛管理
  • 神經性疼痛
  • 偏頭痛
  • 腰痛
  • 骨關節炎的疼痛
  • 癌症的疼痛
  • 其他
  • 咳嗽的治療
  • 便秘的治療

第6章 各地區預測

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第7章 競爭環境

  • 熱圖分析
  • 市場佔有率分析
  • 企業簡介
  • 分析師的見解

第8章 章節

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Opioid drugs bind to opioid receptors that are present in several areas of the nervous system such as the brain and spinal cord. Medically, they are primarily being used for pain relief. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids. However, its application is not limited to pain relief alone and has been successfully used for treatment of various other medical conditions such as diarrhea and cough. Opioid drugs can be broadly divided into two categories, mild and major opioids, on the basis of its efficacy. Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges. Overdose and drug abuse is a major concern, with the situation alarming in developed regions. According to World Drug Report 2017, 29.5 million people suffered from drug use disorders in 2015 and staggering 70% of this 29.5 million were attributed to opioids only.

Market Dynamics

Incidence of chronic pain, which is primarily treated by opioids has witnessed continuous growth over the last decades. According to a report titled Pain in Europe, published in 2006, chronic pain affected around one in five (19%) adults, and prevalence was recorded to be the highest in Norway, Poland, and Italy, where one-fourth of adults were suffering from chronic pain. According to a study titled Prevalence of Chronic Pain in the UK, published in The BMJ (British Medical Journal), in 2013, chronic pain affects between one-third and one-half of the population in the U.K, indicating high prevalence rate. Prevalence rate is similar in other developed countries such as the U.S. Rapidly increasing incidence of chronic pain is thus expected to boost growth of the opioids market over the forecast period.  

However, increasing usage of opioids, has led to increase in its overuse or abuse over the recent past. To tackle this situation, CDC published guidelines for prescribing opioids for chronic pain. Similar efforts to curtail opioid overuse are underway in developed economies of Europe. Such intervention by regulatory bodies are expected to obstruct growth of the opioids market.  

Key Features of the Study:

This report provides in-depth analysis of the opioids market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2014 & 2015 as the base years

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global opioids market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, and Pfizer Inc.

Insights from this report will allow marketers and the management authorities of companies to make informed decision with respect to their future product launch, technology upgrades, market expansion, and marketing tactics

The global opioids market report caters to various stakeholders in this industry, including investors, geriatric care service providers, assistive device manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the opioids market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Opioids Market, By Drug Class:
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • Global Opioids Market, By Therapeutic Application:
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Global Opioids Market, By Geography:
  • North America
  • U.S.
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Canada
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Europe
  • U.K.
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Germany
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Italy
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • France
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Spain
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Russia
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Rest of Europe
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Asia-Pacific
  • China
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • India
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Japan
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • ASEAN
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Australia
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • South Korea
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Rest of Asia Pacific
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Latin America
  • Brazil
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Mexico
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Argentina
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Rest of Latin America
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Middle East
  • GCC
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Israel
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Rest of Middle East
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Africa
  • North Africa
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Central Africa
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • South Africa
  • By Drug Class
  • Agonist
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Morphine
  • Hydrocodone
  • Diphenoxylate
  • Hydromorphone
  • Methylphenidate
  • Oxycodone
  • Oxymorphone
  • Antagonist
  • Buprenorphine
  • Naloxone
  • Naltrexone
  • Methylnaltrexone
  • Nalbuphine
  • By Therapeutic Application
  • Pain Management
  • Neuropathic Pain
  • Migraine
  • Back Pain
  • Osteoarthritis Pain
  • Cancer Pain
  • Others
  • Cough Treatment
  • Diarrhea Treatment
  • Company Profiles
  • Purdue Pharma*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Titan pharmaceuticals
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals, Inc.
  • Sanofi
  • Sun Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Egalet Corporation
  • Endo Pharmaceuticals Inc.
  • Allergan, Plc
  • Pfizer Inc.
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Therapeutic Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Reimbursement Scenario
  • Pricing Analysis
  • New Product Launches
  • Government Policies and Initiatives

4. Global Opioids Market, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)

  • Introduction
    • Market Share Analysis, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, 2014 - 2024
    • Segment Trends
  • Agonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Codeine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Fentanyl
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Meperidine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Methadone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Morphine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Hydrocodone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Diphenoxylate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Hydromorphone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Methylphenidate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Oxycodone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Oxymorphone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Antagonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Buprenorphine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Naloxone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Naltrexone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Methylnaltrexone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  • Nalbuphine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)

5. Global Opioids Market, By Therapeutic Application, 2014 - 2024 (US$ Million & No. of Units)

  • Introduction
    • Market Share Analysis, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, 2014 - 2024
    • Segment Trends
  • Pain Management
    • Introduction
    • Market Share Analysis, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, 2014 - 2024
  • Neuropathic Pain
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  • Migraine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  • Back Pain
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  • Osteoarthritis Pain
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  • Cancer Pain
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  • Cough Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  • Diarrhea Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)

6. Global Opioids Market, By Regions, 2014 - 2024 (US$ Million & No. of Units)

  • Introduction
    • Market Share Analysis, By Region, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, For Regions, 2014 - 2024
  • North America
    • Market Share Analysis, By Country, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, By Country, 2014 - 2024
  • U.S.
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Canada
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Europe
    • Market Share Analysis, By Country, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, By Country, 2014 - 2024
  • U.K.
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Germany
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Italy
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • France
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Russia
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Rest of Europe
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Asia Pacific
    • Market Share Analysis, By Country, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, By Country, 2014 - 2024
  • China
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • India
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Japan
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • ASEAN
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Australia
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • South Korea
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Rest of Asia Pacific
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Latin America
    • Market Share Analysis, By Country, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, By Country, 2014 - 2024
  • Brazil
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Mexico
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Rest of Latin America
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Africa
    • Market Share Analysis, By Country, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, By Country, 2014 - 2024
  • Northern Africa
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Central Africa
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • South Africa
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Middle East
    • Market Share Analysis, By Country, 2015 and 2024 (%)
    • Y-o-Y Growth Analysis, By Country, 2014 - 2024
  • GCC Countries
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Israel
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  • Rest of Middle East
    • Country Trends
    • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)

7. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
    • Purdue Pharma
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Titan Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Boehringer Ingelheim
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Janssen Pharmaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Sanofi
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Mallinckrodt Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Egalet Corporation
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Endo Pharmaceuticals Inc
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Allergan Plc
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Pfizer Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
    • Sun Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact

Browse 130 market data tables and 42 figures on "Opioids Market - Global forecast to 2024".

Back to Top